Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug composition for angiogenesis therapy

A pharmaceutical composition and angiogenesis technology, which can be used in drug combinations, microorganisms, pharmaceutical formulations, etc., and can solve problems such as limited effects of drug therapy

Inactive Publication Date: 2012-07-11
福田惠一 +2
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effect of drug therapy is limited. Endovascular stent therapy and surgical bypass are the first choice for severe cases, but there are many cases that are not suitable for treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composition for angiogenesis therapy
  • Drug composition for angiogenesis therapy
  • Drug composition for angiogenesis therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0068] Hereinafter, the present invention will be specifically explained through examples, but the present invention is not limited by these examples at all.

[0069] Construction of plasmid and adeno-associated virus (AAV) vector

[0070] The construction method of the human PGIS expression vector is briefly explained: the restriction endonuclease HindIII / BamHI fragment of the full-length human PGIS cDNA is smoothed, and the obtained fragment and the pUC-CAGGS expression plasmid are digested and smoothed with XhoI Location connection. In order to confirm that the pUC / PGIS construct encodes a biologically active PGIS protein, the pUC / PGIS vector was transfected into NIH3T3 cells, and the conversion of [14C]-PGH2 to 6-keto-[14C]-PGF1α was measured. The uninserted pUC-CAGGS vector was used as a control vector. Next, the human PGIS gene was inserted into the AAV-CAG plasmid to construct the AAV-hPGIS vector. In addition, a highly active green fluorescent protein (AAV-EGFP) for sub...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a drug composition for angiogenesis therapy that is useful in the treatment or prevention of peripheral arterial diseases; wherein the drug composition is provided with an adeno-associated virus (AAV) that comprises a human prostacyclin synthase (hPGIS) gene responsible for prostaglandin I2 (PGI2), which is a substance having vasodilator action and / or platelet aggregation inhibiting activity, and also comprises a gene that encodes angiogenesis factors. By administering the drug composition to sites that are the objective of therapy, gene introduction into AAV type 1-hPGIS skeletal muscles is achieved, prominent human PGIS gene expression is caused within the skeletal muscle cells, the PGI2 produced and secreted from the muscle cells through the gene expression causes vascular protection activity and angiogenesis-inducing activity, and vascular ischemia is ameliorated.

Description

Technical field [0001] The present invention relates to a pharmaceutical composition useful for angiogenesis therapy and an enhancer for enhancing angiogenesis. Background technique [0002] In the context of a westernized lifestyle and an aging society, the number of patients with peripheral arterial disease (PAD) is gradually increasing. The PAD is a disease based on arteriosclerosis, and age, smoking, diabetes, hypertension, abnormal lipid metabolism, etc. become risk factors for the PAD. In addition, according to a report by the American Heart Association, with the spread of non-invasive tests that detect PAD, the prevalence of PAD by the age of 50 is approximately 2 to 3%, and that of over 75 years is approximately 20%. In addition, it is said that about 40% of PAD patients are asymptomatic. [0003] Currently, as the treatment of this PAD, there are: anti-platelets (anti-platelets), vasodiator (vasodiator), prostanoid (prostanoid) as the center of drug therapy, endovascular...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K31/5585A61K35/76A61K38/22A61K38/43A61P7/02A61P9/00A61P9/08A61P43/00A61K35/13
CPCA61K31/5585A61K38/1825A61K45/06A61K38/1866A61K38/52C12N2799/025A61K38/1833A61K35/13A61K48/005C12Y503/99004A61P35/00A61P43/00A61P7/02A61P9/00A61P9/08A61P9/10A61K2300/00A61K35/76C12N7/00C12N2750/14132C12N2750/14143
Inventor 福田惠一川上崇史田边忠
Owner 福田惠一
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com